Dr Reddy's Labs launches generic injection indicated for abortion in US

Image
Press Trust of India New Delhi
Last Updated : Jul 03 2019 | 2:00 PM IST

Dr Reddy's Laboratories Wednesday said it has launched in the US generic Carboprost Tromethamine injection used for aborting pregnancy.

The company has launched Carboprost Tromethamine injection USP, 250 mcg/mL (1mL) single-dose vial in the US market, the pharma major said in a filing to BSE.

The product is a generic version of Pfizer's Hemabate injection in the strength of 250 mcg/mL, it added.

"We are pleased to be first-to-market with this product that has been designated as a Competitive Generic Therapy (CGT) by the FDA," Dr Reddy's Laboratories North America Generics CEO Marc Kikuchi said.

With a CGT designation, the company has 180-day CGT exclusivity to market this product, he added.

As per IQVIA Health data, Hemabate injection, 250 mcg/mL brand had US sales of approximately USD 55 million MAT for the twelve months ended April 2019, Dr Reddy's Labs said.

Shares of Dr Reddy's Labs were trading at Rs 2,590 per scrip on BSE, down 1.46 per cent from the previous close.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 03 2019 | 2:00 PM IST

Next Story